NCT01280240已完成1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Total serum iron pharmacokinetic parameters: AUC0-t, AUC Cmax, Tmax, Ke, and T1/2 estimated from plasma/serum concentration profile from exposure to 7 days post-exposure.
研究概览
简要总结
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, aged more than 18 years.
- •Weight above 50 kg.
- •Subjects diagnosed with non-hematological malignancies (solid tumors only) receiving chemotherapy at least 1 day prior to screening and who are going to receive at least two more chemotherapy cycles.
- •Hb < 12 g/dL.
- •Serum Ferritin <800 ng/ml.
- •An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Willingness to participate after informed consent.
排除标准
- •Anaemia caused primarily by other factors than CIA.
- •IV or oral iron treatment within 4 weeks prior to screening visit.
- •Erythropoietin treatment within 4 weeks prior to screening visit.
- •Blood transfusion within 4 weeks prior to screening visit.
- •Imminent expectation of blood transfusion on part of treating physician.
- •Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- •Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes).
- •Known hypersensitivity to any excipients in the investigational drug products.
- •Subjects with a history of multiple allergies.
- •Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALAT) > 3 times upper normal limit).
- •History of Immunocompromise and/or history of Hepatitis B and/or C.
- •Active acute or chronic infections (assessed by clinical judgement and if deemed necessary by investigator supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- •Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •Pregnant or breast feeding women.
- •Women of child bearing potential who are not using safe contraceptive methods (e.g. intrauterine device, oral contraceptives or surgically sterilized) or who are planning to become pregnant within the study period.
- •Planned elective surgery during the study.
- •Participation in any other clinical study (except chemotherapy protocol) within 3 months prior to screening.
- •Untreated B12 or folate deficiency.
- •Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
研究组 & 干预措施
Monofer 250 mg
Active Comparator
干预措施: Monofer(R) (Drug)
Monofer 500 mg
Active Comparator
干预措施: Monofer(R) (Drug)
结局指标
主要结局
Total serum iron pharmacokinetic parameters: AUC0-t, AUC Cmax, Tmax, Ke, and T1/2 estimated from plasma/serum concentration profile from exposure to 7 days post-exposure.
时间窗: 0-7 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)Chronic Kidney DiseaseNCT01469078Pharmacosmos A/S18
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)Non-hematological MalignanciesNCT01213979Pharmacosmos A/S16
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKDNon-dialysis Dependent Chronic Kidney DiseaseNCT01213992Pharmacosmos A/S16
已完成
1 期
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel DiseaseInflammatory Bowel DiseaseNCT01213680Pharmacosmos A/S16
已完成
3 期
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucroseIron Deficiency AnaemiaNCT02130063Pharmacosmos A/S511